Development

J&J and Biogen Discuss Their Biosimilar Strategies at J.P. Morgan Healthcare Conference

January 8th 2019

By Samantha DiGrande

Presenters during the 37th annual J.P. Morgan Healthcare Conference, held January 7-10 in San Francisco, California provided an overview about what potential investors can expect to see from their companies’ pharmaceutical pipelines over the next fiscal year.

Pfizer and Teva Provide a Look at Their Biosimilar Ambitions on Day 1 of the J.P. Morgan Healthcare Conference

January 7th 2019

By Kelly Davio

During the first day of the 37th Annual J.P. Morgan Healthcare Conference, held January 7-10 in San Francisco, California, 2 major biosimilar developers gave a look at their strategies for 2019 and beyond.

The FDA Biosimilar Action Plan: Making Biologics More Accessible

December 7th 2018

While other stakeholders also need clarification of the FDA policies, it is the developers who will make it possible to bring lower-cost biosimilars to make a real difference. In this paper, I am providing comments on the proposed action plans of the FDA and pointing out what I believe to be the missing elements.

Could Biosimilars of Orphan Drugs Reduce Patients' Cost Burdens?

October 30th 2018

By Kelly Davio

In recent years, spending on specialty drugs, including spending on a proliferation of orphan drugs that treat rare diseases, has raised concerns about sustainability of the healthcare system.

The Clinical Trials Landscape Is Evolving in Biosimilar Development

October 22nd 2018

By Kelly Davio

Among the hottest topics in biosimilar development is the future of clinical trials, and that fact was evident during the opening session of the fifth DIA Biosimilars Conference, held October 22 to 23 in London, United Kingdom. During the presentation, a review of the biosimilar regulatory framework, 4 experts explained the ways in which the landscape for clinical trials is evolving for biosimilars.

Outlook on the Future of Biosimilars

October 10th 2018

Biosimilars in the Pipeline and Disease Management

October 10th 2018

The Influence of Biosimilars in Cancer Care

October 10th 2018

Prescribing Biosimilars and Educating Patients and Physicians

October 10th 2018

Formulary Approval and Challenges for Payers

October 10th 2018